CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Coherus Oncology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$0.96−0.03 (-3.16%)

Close on Oct 19, 2026

Market cap: $148.42M
P/E (TTM): 0.7
Dividend yield: –

Coherus Oncology, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Revenue	42	26	257	211	327	476	356	0	1.56	190	30	31	2.75	1.90
Cost of Revenue	14	8.73	159	70	58	38	17	–	–	–	–	–	–	–
Gross Profit	28	18	98	141	269	438	339	–	–	–	–	–	–	–
Research & Development	109	92	109	199	363	143	94	110	162	254	213	78	31	35
Selling, General & Admin	101	125	192	198	170	139	137	94	71	52	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	71	52	36	18	7.47	5.53
Advertising Expenses	6.60	7.40	11	11	8.70	3.80	4.50	2.80	0	0	–	–	–	–
Operating Expenses	–	–	–	–	–	–	248	204	234	306	249	96	39	40
Total Costs & Expenses	223	226	460	468	590	320	248	204	–	–	–	–	–	–
Operating Income	-181	-200	-203	-257	-264	156	108	-204	-232	-116	-219	-65	-36	-39
Interest Expense	9.00	11	41	32	23	21	18	9.68	9.55	7.98	0.03	3.90	5.29	1.51
Interest & Investment Income	7.00	4.50	2.80	1.90	1.40	0.60	1.60	1.40	–	–	–	–	–	–
Other Non-Operating Income	7.01	7.62	5.47	3.82	-0.28	0.55	2.61	4.69	3.40	-3.88	-4.84	-19	-12	7.01
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	3.60	–	–	–	–	–
Asset Impairment Charges	–	–	0	0	0	0	0	3.90	0.60	–	0.40	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	0	0	-0.05	0.01	–	–	–	–
Pretax Income	-183	-215	-238	-292	-287	136	93	-209	-238	–	–	–	–	–
Income Tax Expense	0	0	-0.38	0	0	3.46	2.94	0	0	0	0	0	–	–
Income from Continuing Operations	-183	-215	–	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	351	244	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	168	29	-238	-292	-287	132	90	-209	-238	-128	-224	-87	-54	-33
Minority Interest in Earnings	–	–	–	–	–	–	0	-0.07	-0.12	-0.45	-0.68	-0.04	–	–
Net Income	168	29	-238	-292	-287	132	90	-209	-238	-127	-223	-87	-54	-33
EPS (Basic)(per share)	1.43	0.25	-2.53	-3.76	-3.81	1.85	1.29	-3.22	-4.48	-3.04	-6.01	-10.64	-16.10	-15.85
EPS (Diluted)(per share)	1.43	0.25	-2.53	-3.76	-3.81	1.62	1.23	-3.22	-4.48	-3.04	-6.01	-10.64	-16.10	-15.85
Shares Outstanding (Basic, Weighted)(shares)	117	115	94	78	75	71	70	65	53	42	37	8.19	4.83	4.96
Shares Outstanding (Diluted, Weighted)(shares)	117	115	94	78	75	83	73	65	53	42	37	8.19	3.33	2.08
EBITDA	-180	-198	-200	-253	-260	159	111	-201	-229	-113	-217	-64	-36	-38

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 68.9%
Operating margin: -311.6%
Net margin: -259.4%
Return on equity, FY2025: -473.5%

Financial strength

Current ratio: 1.77
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 109.8%

Valuation

P/E ratio: 0.7
Price to sales: 2.91
Price to book: 2.44
Dividend yield: –